Calcium channel agonist, (±)-Bay K8644, causes an immediate increase in the striatal 1-methyl-4-phenylpyridinium level following systemic administration of the dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in Balb/c mice

Neuroscience Letters

Volumn 346, Issue 1-2, 2003, Pages 69-72

  Samantaray, Supriti ^a   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine metabolism, neurodegeneration and neuroprotection; Acute effects of 1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Calcium channels; Monoamine oxidase B

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CALCIUM CHANNEL; CALCIUM CHANNEL STIMULATING AGENT; DOPAMINE; NEUROTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; ELECTROCHEMICAL ANALYSIS; ENZYME ACTIVITY; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NEUROTOXICITY; NONHUMAN; PHOTOMETRY; PRIORITY JOURNAL; SPECTROFLUOROMETRY;

EID: 0037707634     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00577-9     Document Type: Article

References (22)

1. Blosser J.C., McCreedy S., Parker R.B., Kinsolving C.R., Watkins B.E., Wu E.S. Flavodilol: a new antihypertensive agent that preferentially depletes peripheral biogenic amines. J. Cardiovasc. Pharmacol. 14:1989;142-156.
2. Castagnoli K., Palmer S., Anderson A., Bueters T., Castagnoli N. Jr. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 10:1997;364-368.
3. Chiba K., Trevor A., Castagnoli N. Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:1984;574-578.
4. Chiueh C.C., Miyake H., Peng M.T. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism. Adv. Neurol. 60:1993;251-258.
5. Hallman H., Lange J., Olson L., Stromberg I., Jonsson G. Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. J. Neurochem. 44:1985;117-127.
6. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin. Eur. J. Pharmacol. 106:1984;455-456.
7. +-evoked release of dopamine from rat striatal slices. Neurosci. Lett. 187:1995;123-126.
8. Kupsch A., Gerlach M., Pupeter S.C., Sautter J., Dirr A., Arnold G., Opitz W., Przuntek H., Riederer P., Oertel W.H. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. NeuroReport. 6:1995;621-625.
9. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
10. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 311:1984;464-467.
11. Mitra N., Mohanakumar K.P., Ganguly D.K. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase-B. J. Neurochem. 62:1994;1906-1912.
12. Mohanakumar K.P., Samantaray S., Busselberg D. The parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydripyridin on membrane currents and intrasynaptosomal calcium. Neurosci. Res. Commun. 30:2002;35-42.
13. Morinan A., Garratt H.M. An improved fluorimetric assay for brain monoamine oxidase. J. Pharmacol. Methods. 13:1985;213-223.
14. 2+ channels on excessive dopamine release from rat caudate putamen. Physiol. Behav. 68:2000;641-649.
15. Olanow C.W. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov. Disord. 8:(Suppl. 1):1993;S1-S7.
16. Olanow C.W. MAO-B inhibitors in Parkinson's disease. Adv. Neurol. 60:1993;666-671.
17. 3H] dopamine release from rat striatal synaptosomes by voltage-sensitive calcium channel ligands. Biochem. Pharmacol. 52:1996;613-618.
18. Samantaray S., Chandra G., Mohanakumar K.P. Calcium channel agonist, (±)-Bay K8644, causes a transient increase in striatal monoamine oxidase activity in Balb/c mice. Neurosci. Lett. 2003;. in press.
19. Thomas B., Muralikrishnan D., Mohanakumar K.P. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. 852:2000;221-224.
20. Usha R., Muralikrishnan D., Thomas B., Ghosh S., Mandal C.N., Mohanakumar K.P. Region specific attenuation of a trypsin like protease in substantia nigra following dopaminergic neurotoxicity by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 882:2000;191-195.
21. 2+ channel in the brain. Life Sci. 62:1998;1671-1675.
22. Woodward J.J., Cook M.E., Leslie S.W. Characterization of dihydropyridine-sensitive calcium channels in rat brain synaptosomes. Proc. Natl. Acad. Sci. USA. 85:1988;7389-7393.